1. Shimoyama M, Ogino K, Furuse Y, et al. Signaling pathway and chronotropic action of parathyroid hormone in isolated perfused rat heart. J Cardiovasc Pharmacol 2001; 38: 491–499.
2. Crass MF 3rd, Moore PL, Strickland ML, et al. Cardiovascular responses to parathyroid hormone. Am J Physiol 1985; 249 (2 Pt 1): E187–E194.
3. Sambrook PN, Chen JS, March LM, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab 2004; 89: 5477–5481.
4. Nilsson IL, Wadsten C, Brandt L, et al. Mortality in sporadic primary hyperparathyroidism: nationwide cohort study of multiple parathyroid gland disease. Surgery 2004; 136: 981–987.
5. Tanaka M, Tokunaga K, Maruyama T, et al. Parathyroidectomy markedly reduces oxidative stress in a patient with primary hyperparathyroidism. Ther Apher Dial 2011; 15 (1 suppl): 38–41.
6. Vestergaard H, Østergaard Kristensen L. Normocalcemia and persistent elevated serum concentrations of 1-84 parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of increased morbidity from cardiovascular disease. World J Surg 2002; 26: 657–660.
7. Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology 2009; 55: 601–606.
8. Carlstedt F, Lind L, Wide L, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest 1997; 27: 977–981.
9. Fisher A, Goh S, Srikusalanukul W, et al. Elevated serum PTH is independently associated with poor outcomes in older patients with hip fracture and vitamin D inadequacy. Calcif Tissue Int 2009; 85: 301–309.
10. Cawthon PM, Parimi N, Barrett-Connor E, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab 2010; 95: 4625–4634.
11. Bozic B, Loncar G, Prodanovic N, et al. Parathyroid hormone response to vitamin D insufficiency in elderly males with chronic heart failure. Physiol Res 2011; 60: S155–S163.
12. Chen JS, Sambrook PN, March L, et al. Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol (Oxf) 2008; 68: 290–298.
13. Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506–1523.
14. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–2138.
15. Linhartová K, Veselka J, Sterbáková G, et al. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008; 72: 245–250.
16. Schmitz F, Ewering S, Zerres K, et al. Parathyroid hormone gene variant and calcific aortic stenosis. J Heart Valve Dis 2009; 18: 262–267.
17. Neves KR, Graciolli FG, dos Reis LM, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262–1270.
18. Akmal M, Barndt RR, Ansari AN, et al. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int 1995; 47: 158–163.
19. Amin M, Fawzy A, Hamid MA, et al. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124: 2093–2097.
20. Coen G, Ballanti P, Mantella D, et al. Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study. Am J Nephrol 2009; 29: 145–152.
21. Goldsmith DJ, Covic A, Sambrook PA, et al. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37–43.
22. Zouboulis CC, Blume-Peytavi U, Lennert T, et al. Fulminant metastatic calcinosis with cutaneous necrosis in a child with end-stage renal disease and tertiary hyperparathyroidism. Br J Dermatol 1996; 135: 617–622.
23. Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003; 18: 1770–1776.
24. Cozzolino M, Ronco C. The impact of paricalcitol on left ventricular hypertrophy. Contrib Nephrol 2011; 171: 161–165.
25. Wei M, Esbaei K, Bargman JM, et al. Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease? Int Urol Nephrol 2006; 38: 317–322.
26. Cheng SL, Shao JS, Halstead LR, et al. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res 2010; 107: 271–282.
27. Hörl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19 (5 suppl): V2–V8.
28. Potthoff SA, Janus A, Hoch H, et al. PTH-receptors regulate norepinephrine release in human heart and kidney. Regul Pept 2011; 171: 35–42.
29. Bhuriya R, Li S, Chen SC, et al. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53 (4 suppl 4): S3–S10.
30. Lishmanov A, Dorairajan S, Pak Y, et al. Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 2011;Feb 15 [Epub ahead of print].
31. Zitt E, Kirsch AH, Haueis M, et al. The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients. Clin Nephrol 2011; 75: 309–318.
32. Avram MM, Mittman N, Myint MM, et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351–1357.
33. Dimkovic NB, Bargman J, Vas S, et al. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2002; 22: 204–210.
34. Drechsler C, Krane V, Grootendorst DC, et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant 2009; 24: 3151–3157.
35. Drechsler C, Grootendorst DC, Boeschoten EW, et al. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant 2011; 26: 1340–1346.
36. New N, Mohandas J, John GT, et al. Calcific uremic arteriolopathy in peritoneal dialysis populations. Int J Nephrol 2011; 2011: 982854.
37. Agapitou V, Dimopoulos S, Mpouchla A, et al. Serum intact parathyroid hormone levels independently predict exercise capacity in stable heart failure patients. Int J Cardiol 2011; 146: 462–464.
38. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D—markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011; 13: 626–632.
39. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart 2009; 95: 395–398.
40. Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 2010; 12: 1186–1192.
41. Nasri H, Baradaran A. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Bratisl Lek Listy 2004; 105: 368–373.
42. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383–392.
43. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34–41.
44. Ballen KK, Shpall EJ, Avigan D, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13: 838–843.
45. Huber BC, Fischer R, Brunner S, et al. Comparison of parathyroid hormone and G-CSF treatment after myocardial infarction on perfusion and stem cell homing. Am J Physiol Heart Circ Physiol 2010; 298: H1466–H1471.
46. Pagliarulo C, Salvatore P, Napoli C. Targeting vascular niche by parathyroid hormone. Curr Med Chem 2008; 15: 2984–2990.
47. Huber BC, Brunner S, Segeth A, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1–driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res 2011; 90: 529–537.
48. Loncar G, Bozic B, Cvorovic V, et al. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 2010; 37: 148–156.
49. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 69–74.
50. Schillaci G, Pucci G, Pirro M, et al. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 2011; 218: 96–101.
51. Marini C, Giusti M, Armonino R, et al. Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 2010; 37: 2256–2263.
52. Grandi NC, Breitling LP, Hahmann H, et al. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011; 97: 1215–1221.
53. Fisher AA, Southcott EK, Srikusalanukul W, et al. Relationships between myocardial injury, all-cause mortality, vitamin D, PTH, and biochemical bone turnover markers in older patients with hip fractures. Ann Clin Lab Sci 2007; 37: 222–232.
54. Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J 2011; 162: 331.e2–339.e2.
55. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591–1598.
56. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–1800.
57. Hjelmesaeth J, Hofsø D, Aasheim ET, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol 2009; 8: 7.
58. Røislien J, Van Calster B, Hjelmesæth J. Parathyroid hormone is a plausible mediator for the metabolic syndrome in the morbidly obese: a cross-sectional study. Cardiovasc Diabetol 2011; 10: 17.
59. Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 2007; 261: 558–565.
60. Szulc P, Claustrat B, Delmas PD. Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men—the MINOS study. Clin Endocrinol (Oxf) 2009; 71: 594–602.
61. Williams DM, Fraser A, Lawlor DA. Associations of vitamin D, parathyroid hormone and calcium with cardiovascular risk factors in US adolescents. Heart 2011; 97: 315–320.
62. Arad Y, Spadaro LA, Roth M, et al. Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study. Coron Artery Dis 1998; 9: 513–518.
63. Taylor EN, Rimm EB, Stampfer MJ, et al. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011; 161: 956–962.
64. Jiang B, Morimoto S, Yang J, et al. Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol 1998; 31: S142–S144.
65. Perkovic V, Hunt D, Griffin SV, et al. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract 2003; 94: c40–c45.
66. Fritsch S, Lindner V, Welsch S, et al. Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 2004; 15: 2588–2600.
67. Barlet JP, Coxam V, Davicco MJ. Relation between the parathyroid glands and arterial pressure: is there a parathyroid hypertensive factor? Presse Med 1995; 24: 1703–1706.
68. Fardella C, Rodriguez-Portales JA. Intracellular calcium and blood pressure: comparison between primary hyperparathyroidism and essential hypertension. J Endocrinol Invest 1995; 18: 827–832.
69. Barletta G, De Feo ML, Del Bene R, et al. Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 1815–1821.
70. Nyby MD, Hino T, Berger ME, et al. Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone–related protein. Endocrinology 1995; 136: 2497–2504.
71. Iseki K. Parathyroid hormone and the vascular response to norepinephrine. Am J Hypertens 1990; 3: 238S–240S.
72. Smajilovic S, Schaal-Jensen R, Jabbari R, et al. Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats. Open Cardiovasc Med J 2010; 4: 110–116.
73. Perkovic V, Hewitson TD, Kelynack KJ, et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003; 26: 27–33.
74. Somjen D, Weisman Y, Kohen F, et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666–1671.
75. Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 2008; 38: 798–803.
76. Coen G, Mantella D, Sardella D, et al. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients. J Nephrol 2009; 22: 616–622.
77. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18: iii2–iii8.
78. Akmal M, Kasim SE, Soliman AR, et al. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854–858.
79. Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 1985; 75: 1037–1044.
80. Alvarez JA, Ashraf AP, Hunter GR, et al. Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr 2010; 92: 1344–1349.
81. Fraser A, Williams D, Lawlor DA. Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001–2006). PLoS One 2010; 5: e13882.
82. Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant 2006; 21: 2621–2624.
83. Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650–1658.
84. D’Amour P. Circulating PTH molecular forms: what we know and what we don’t. Kidney Int Suppl 2006; 102: S29–S33.
85. Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 2008; 43: 1022–1030.
86. Shao JS, Cheng SL, Charlton-Kachigian N, et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195–50202.
87. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003; 88: 185–191.
88. Stein MS, Wark JD, Scherer SC, et al. Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. J Am Geriatr Soc 1999; 47: 1195–1201.
89. Adami S, Viapiana O, Gatti D, et al. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 2008; 42: 267–270.
90. Soilu-Hänninen M, Laaksonen M, Laitinen I, et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 152–157.
91. Aloia JF, Chen DG, Chen H. The 25(OH)D/PTH threshold in black women. J Clin Endocrinol Metab 2010; 95: 5069–5073.
92. Grant WB, Peiris AN. Possible role of serum 25-hydroxyvitamin D in Black–White health disparities in the United States. J Am Med Dir Assoc 2010; 11: 617–628.
93. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control 2007; 18: 775–782.
94. Lim U, Freedman DM, Hollis BW, et al. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer 2009; 124: 979–986.